Checkpoint inhibitor therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus. Some cancers can protect themselves from attack by stimulating immune checkpoint targets. Checkpoint therapy can block inhibitory checkpoints, restoring immune system function.[1] The first anti-cancer drug targeting an immune checkpoint was ipilimumab, a CTLA4 blocker approved in the United States in 2011.[2]
Currently approved checkpoint inhibitors target the molecules CTLA4, PD-1, and PD-L1. PD-1 is the transmembrane programmed cell death 1 protein (also called PDCD1 and CD279), which interacts with PD-L1 (PD-1 ligand 1, or CD274). PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity. Among PD-L1 functions is a key regulatory role on T cell activities.[3][4] It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T cells that might otherwise attack. Antibodies that bind to either PD-1 or PD-L1 and therefore block the interaction may allow the T-cells to attack the tumor.[5]
The discoveries in basic science allowing checkpoint inhibitor therapies led to James P. Allison and Tasuku Honjo winning the Tang Prize in Biopharmaceutical Science and the Nobel Prize in Physiology or Medicine in 2018.[6][7]
^Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
^Cite error: The named reference Cameron2011 was invoked but never defined (see the help page).
^Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (July 2007). "Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses". Immunity. 27 (1): 111–22. doi:10.1016/j.immuni.2007.05.016. PMC 2707944. PMID 17629517.
^Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D (October 2011). "PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells". EMBO Molecular Medicine. 3 (10): 581–92. doi:10.1002/emmm.201100165. PMC 3191120. PMID 21739608.
^Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
^"2014 Tang Prize in Biopharmaceutical Science". Archived from the original on 2017-10-20. Retrieved 2016-06-18.
^Devlin H (2018-10-01). "James P Allison and Tasuku Honjo win Nobel prize for medicine". The Guardian. Retrieved 2018-10-01.
and 28 Related for: Checkpoint inhibitor information
Checkpointinhibitor therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated...
Svane IM, Donia M (April 2018). "T cells isolated from patients with checkpointinhibitor resistant-melanoma are functional and can mediate tumor regression"...
Checkpointinhibitor induced colitis is an inflammatory condition affecting the colon (colitis), which is caused by cancer immunotherapy (checkpoint inhibitor...
potential for use in multiple types of cancers. Currently approved checkpointinhibitors block CTLA4, PD-1 and PD-L1. For the related basic science discoveries...
steroid-dependent. Vedolizumab may be used to treat steroid refractory checkpointinhibitor induced colitis, if infliximab is ineffective or contraindicated...
approach being much more likely. Biological response modifier Sepsivac Checkpointinhibitor Interleukin-2 immunotherapy Immunostimulant Microtransplantation...
pharmaceuticals, including tislelizumab, a checkpointinhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. In addition to clinical research, BeiGene's...
checkpointinhibitor, ipilimumab (Yervoy), had shown strong promise in treating metastatic melanoma and that a second Bristol Myers Squibb checkpoint...
countries, but today (2024) the most common adjuvant treatment is immune checkpointinhibitor treatment for up to a year post-surgery. In the early 2000's, a relatively...
severe symptoms. Combining standard chemotherapy with an immune checkpointinhibitor can improve survival for a minority of those affected, extending...
Cell cycle checkpoints are control mechanisms in the eukaryotic cell cycle which ensure its proper progression. Each checkpoint serves as a potential termination...
antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpointinhibitor, blocking a signal that prevents activation of T cells from attacking...
principal cholesterol carrier in the brain. APOE qualifies as a checkpointinhibitor of the classical complement pathway by complex formation with activated...
the PD-1 (CD279).[medical citation needed] Durvalumab is an immune checkpointinhibitor drug. The US Food and Drug Administration (FDA) approved durvalumab...
advanced, or metastatic triple-negative breast cancer, combined with a checkpointinhibitor and chemotherapy. As of October 2020[update], five phase I/II clinical...
individuals requiring more intensive chemotherapy options, using an immune checkpointinhibitor may be preferable to long-term use of multi-agent chemotherapy to...
2016 Genentech partnered with the Israeli company BioLineRx on a checkpointinhibitor that Genentech intended to pair with its own atezolizumab. Genentech's...
Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpointinhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma...
programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpointinhibitor. In 2018, toripalimab was approved in China for the treatment of...
diversity in their gut microbiome responded better to an anti-PD-1 checkpointinhibitor versus those with less diversity. Based on this work, the Parker...
Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpointinhibitor that is being investigated for melanoma. This drug is being developed...
metastatic, asymptomatic stage IV prostate cancer. 2010 – First immune checkpointinhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of...
Between 5.7 and 9.1% of individuals treated with ipilimumab develop checkpointinhibitor induced colitis. Individual cases of severe neurologic disorders...
possibility of harm. Infliximab is indicated for steroid refractory checkpointinhibitor induced colitis, at a dose of 5 to 10 mg/kg. Infliximab has adverse...
Monalizumab is a monoclonal antibody targeted at NKG2A. It is a checkpointinhibitor. A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies...
Global Information